Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Animals were immunized with purified CD34 positive human progenitor stem cells, which had been pre-incubated with phytohemagglutinin (PHA).
Lymph node cells were fused with Sp2/0 Ag14 mouse myeloma cells.
The subset of cells recognized by AC133 is CD34bright, and contains substantially all of the CFU-GM activity present in the CD34+ population.
Yin A, et al. Characterization of a human hematopoietic progenitor cell antigen. US Patent 5,843,633 dated Dec 1 1998
Yin AH, et al. Human hematopoietic stem and progenitor cell antigen. US Patent 6,455,678 dated Sep 24 2002
Uchida N, et al. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations. US Patent 6,468,794 dated Oct 22 2002
Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC.
Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988.
Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC.
Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online.
